# High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury

> **NCT00152685** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University Hospital, Angers** · enrollment: 40 (—)

## Conditions studied

- Severe Head Injury

## Interventions

- **DRUG:** human serum albumin

## Key facts

- **NCT ID:** NCT00152685
- **Lead sponsor:** University Hospital, Angers
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2005-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152685, "High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00152685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*